Contemporary Reviews in Cardiovascular Medicine Contemporary Insights and Strategies for Risk Stratification and Prevention of Sudden Death in Hypertrophic Cardiomyopathy

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical Outcome and Phenotypic Expression in LAMP2 Cardiomyopathy

  2011cited by this paper
• Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy

  2009cited by this paper
• Syncope and Risk of Sudden Death in Hypertrophic Cardiomyopathy

  2009cited by this paper
• Prevalence, Clinical Significance, and Natural History of Left Ventricular Apical Aneurysms in Hypertrophic Cardiomyopathy

  2009cited by this paper
• Left ventricular outflow tract obstruction as a risk factor for sudden cardiac death in hypertrophic cardiomyopathy.

  2009cited by this paper
• The case for myocardial ischemia in hypertrophic cardiomyopathy.

  2009cited by this paper
• Multiple Mutations in Genetic Cardiovascular Disease: A Marker of Disease Severity?

  2009cited by this paper
• Long-term survival after cardiac arrest in hypertrophic cardiomyopathy.

  2009cited by this paper
• Circadian patterns in the occurrence of malignant ventricular tachyarrhythmias triggering defibrillator interventions in patients with hypertrophic cardiomyopathy.

  2009cited by this paper
• Ventricular arrhythmia following alcohol septal ablation for obstructive hypertrophic cardiomyopathy.

  2009cited by this paper
• Risk factors and mode of death in isolated hypertrophic cardiomyopathy in children.

  2009cited by this paper
• Myocardial bridging, a frequent component of the hypertrophic cardiomyopathy phenotype, lacks systematic association with sudden cardiac death.

  2009cited by this paper
• Early failure of a small diameter high-voltage implantable cardioverter-defibrillator lead.

  2008cited by this paper
• Clinical Profile and Significance of Delayed Enhancement in Hypertrophic Cardiomyopathy

  2008cited by this paper
• Benefits of the implantable cardioverter-defibrillator.

  2008cited by this paper
• ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities.

  2008cited by this paper
• Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy.

  2008cited by this paper
• Implantable Defibrillators and Prevention of Sudden Death in Hypertrophic Cardiomyopathy

  2008cited by this paper
• A critical appraisal of implantable cardioverter-defibrillator therapy for the prevention of sudden cardiac death.

  2008cited by this paper
• Paced ventricular electrogram fractionation predicts sudden cardiac death in hypertrophic cardiomyopathy.

  2008cited by this paper
• Circadian Rhythm of Appropriate Implantable Cardioverter Defibrillator Discharges in Patients with Hypertrophic Cardiomyopathy

  2008cited by this paper
• Outcome of Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy

  2008cited by this paper
• Results of a multicenter retrospective implantable cardioverter-defibrillator registry of pediatric and congenital heart disease patients.

  2008cited by this paper
• Sudden cardiac arrest in hypertrophic cardiomyopathy in the absence of conventional criteria for high risk status.

  2008cited by this paper
• Significance of Appropriate Defibrillator Shock 3 Hours and 20 Minutes Following Implantation in a Patient with Hypertrophic Cardiomyopathy

  2008cited by this paper
• Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance.

  2008cited by this paper
• Evidence that pharmacological strategies lack efficacy for the prevention of sudden death in hypertrophic cardiomyopathy

  2007cited by this paper
• Electrophysiologic Manifestations of Ventricular Tachyarrhythmias Provoking Appropriate Defibrillator Interventions in High‐Risk Patients with Hypertrophic Cardiomyopathy

  2007cited by this paper
• Determinants of implantable defibrillator discharges in high-risk patients with hypertrophic cardiomyopathy

  2007cited by this paper
• Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.

  2007cited by this paper
• Sudden Death Prevention With Implantable Devices

  2007cited by this paper
• Electrophysiological interventions for inherited arrhythmia syndromes.

  2007cited by this paper
• Early failure of a small-diameter high-voltage implantable cardioverter-defibrillator lead.

  2007cited by this paper
• Genetic Basis of Hypertrophic Cardiomyopathy: From Bench to the Clinics

  2007cited by this paper
• Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy.

  2007cited by this paper
• Hypertrophic cardiomyopathy, sudden death, and implantable cardiac defibrillators: how low the bar?

  2007cited by this paper
• Transvenous implantable cardioverter-defibrillator leads: the weakest link.

  2007cited by this paper
• Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a systematic review of published studies.

  2006cited by this paper
• Prevalence, Clinical Profile, and Significance of Left Ventricular Remodeling in the End-Stage Phase of Hypertrophic Cardiomyopathy

  2006cited by this paper
• ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines

  2006cited by this paper
• Hypertrophic Cardiomyopathy Is Predominantly a Disease of Left Ventricular Outflow Tract Obstruction

  2006cited by this paper
• Use of echocardiography in patients with hypertrophic cardiomyopathy: clinical implications of massive hypertrophy.

  2006cited by this paper
• Transcoronary Ablation of Septal Hypertrophy Does Not Alter ICD Intervention Rates in High Risk Patients with Hypertrophic Obstructive Cardiomyopathy

  2005cited by this paper
• Relation of electrocardiographic patterns to phenotypic expression and clinical outcome in hypertrophic cardiomyopathy.

  2005cited by this paper
• 36th Bethesda Conference: Eligibility Recommendations for Competitive Athletes With Cardiovascular Abnormalities

  2005cited by this paper
• Cardioverter-defibrillator implantation in high-risk patients with hypertrophic cardiomyopathy.

  2005cited by this paper
• Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy.

  2005cited by this paper
• Lessons From the Failure and Recall of an Implantable Cardioverter-Defibrillator

  2005cited by this paper
• Sustained Ventricular Tachycardia Following Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy

  2005cited by this paper
• Myocardial infarction after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: evaluation by contrast-enhanced magnetic resonance imaging.

  2004cited by this paper
• Psychosocial factors and quality of life in children and adolescents with implantable cardioverter-defibrillators.

  2004cited by this paper
• Long-Term Clinical Course of Patients After Termination of Ventricular Tachyarrhythmia by an Implanted Defibrillator

  2004cited by this paper
• Long-term follow-up of implantable cardioverter defibrillator therapy for hypertrophic cardiomyopathy.

  2004cited by this paper
• Deaths associated with implantable cardioverter defibrillator failure and deactivation reported in the United States Food and Drug Administration Manufacturer and User Facility Device Experience Database.

  2004cited by this paper
• Ventricular tachycardia complicating alcohol septal ablation.

  2004cited by this paper
• Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients.

  2003cited by this paper
• Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy.

  2003cited by this paper
• Adverse Prognosis of Patients With Hypertrophic Cardiomyopathy Who Have Epicardial Coronary Artery Disease

  2003cited by this paper
• Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance.

  2003cited by this paper
• Morphology of necrosis and repair after transcoronary ethanol ablation of septal hypertrophy.

  2003cited by this paper
• Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy.

  2003cited by this paper
• Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy.

  2003cited by this paper
• Sudden death in young athletes.

  2003cited by this paper
• American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice G

  2003cited by this paper
• Hypertrophic cardiomyopathy: a systematic review.

  2002cited by this paper
• Hypertrophic cardiomyopathy: management, risk stratification, and prevention of sudden death

  2002cited by this paper
• Prevalence and age-dependence of malignant mutations in the beta-myosin heavy chain and troponin T genes in hypertrophic cardiomyopathy: a comprehensive outpatient perspective.

  2002cited by this paper
• Impact of Atrial Fibrillation on the Clinical Course of Hypertrophic Cardiomyopathy

  2001cited by this paper
• Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy.

  2001cited by this paper
• Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population.

  2000cited by this paper
• Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy.

  2000cited by this paper
• Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy.

  2000cited by this paper
• Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death.

  2000cited by this paper
• Sudden death in hypertrophic cardiomyopathy: identification of high risk patients.

  2000cited by this paper
• The utilization of the implantable defibrillator--a European enigma.

  2000cited by this paper
• Clinical course of hypertrophic cardiomyopathy in a regional United States cohort.

  1999cited by this paper
• Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy.

  1999cited by this paper
• Prevalence of Hypertrophic Cardiomyopathy in a General Population of Young Adults: Echocardiographic Analysis of 4111 Subjects in the Cardia Study

  1996cited by this paper
• Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population.

  1995cited by this paper
• Hypertrophic cardiomyopathy. Clinical spectrum and treatment.

  1995cited by this paper
• Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults.

  1995cited by this paper
• Management of hypertrophic cardiomyopathy.

  1993cited by this paper
• Impact of patient selection biases on the perception of hypertrophic cardiomyopathy and its natural history.

  1993cited by this paper
• Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy.

  1992cited by this paper
• Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy.

  1986cited by this paper
• Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia.

  1985cited by this paper
• Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings.

  1980cited by this paper
• Quantitative Analysis of Cardiac Muscle Cell Disorganization in the Ventricular Septum of Patients with Hypertrophic Cardiomyopathy

  1979cited by this paper
• Idiopathic Hypertrophic Subaortic Stenosis: I. A Description of the Disease Based Upon an Analysis of 64 Patients

  1964cited by this paper
• ASYMMETRICAL HYPERTROPHY OF THE HEART IN YOUNG ADULTS

  1958cited by this paper

• Comparison of two genetic strategies for diagnostic work-up of hypertrophic cardiomyopathy: impact on the diagnosis of Fabry disease or transthyretin amyloidosis

  2025cites this paper
• Global Longitudinal Strain May Be the One that Appropriately Identifies Candidates of ICD Implantation

  2024cites this paper
• Cytokeratin 18 as a Novel Biomarker in Patients with Hypertrophic Cardiomyopathy

  2024cites this paper
• Description of a Cohort with a New Truncating MYBPC3 Variant for Hypertrophic Cardiomyopathy in Northern Spain

  2023cites this paper
• Negative correlation between organ heteroplasmy, particularly hepatic heteroplasmy, and age at death revealed by post-mortem studies of m.3243A > G cases.

  2023cites this paper
• Sudden Death Risk Assessment in Hypertrophic Cardiomyopathy Across the Lifespan: Reconciling the American and European Approaches.

  2023cites this paper
• A maladaptive feedback mechanism between the extracellular matrix and cytoskeleton contributes to hypertrophic cardiomyopathy pathophysiology

  2023cites this paper
• The Role of Cardiopulmonary Exercise Testing in Hypertrophic Cardiomyopathy

  2023cites this paper
• Late gadolinium enhancement entropy as a new measure of myocardial tissue heterogeneity for prediction of adverse cardiac events in patients with hypertrophic cardiomyopathy

  2023cites this paper
• Current perspectives of sudden cardiac death management in hypertrophic cardiomyopathy

  2023cites this paper
• Hypertrophic Obstructive Cardiomyopathy: Comparison of Outcomes After Myectomy or Alcohol Ablation

  2022cites this paper
• Effect of maternal pregestational diabetes mellitus on congenital heart diseases

  2022cites this paper
• Current and emerging perspectives on pathophysiology, diagnosis and management of Hypertrophic Cardiomyopathy.

  2022cites this paper
• Surgical Ablation of Ventricular Tachycardia.

  2022cites this paper
• Left Atrial Dysfunction as Marker of Arrhythmic Events in Patients with Hypertrophic Cardiomyopathy

  2022cites this paper
• Atrial fibrillation and the risk of sudden cardiac arrest in patients with hypertrophic cardiomyopathy - A nationwide cohort study

  2021cites this paper
• Perioperative management of hypertrophic cardiomyopathy for patients undergoing noncardiac surgery ― Perioperative management of HCM ―

  2021cites this paper
• Translational investigation of electrophysiology in hypertrophic cardiomyopathy

  2021cites this paper
• Cellular models and therapeutic perspectives in hypertrophic cardiomyopathy

  2021cites this paper
• Left intraventricular pressure gradient in hypertrophic cardiomyopathy patients receiving implantable cardioverter-defibrillators for primary prevention

  2021cites this paper
• Hypertrophic Cardiomyopathy-Anesthesia Considerations for Septal Myectomy

  2021cites this paper
• Novel pathogenic variant of MYBPC3 responsible for hypertrophic cardiomyopathy

  2021cites this paper
• Pathophysiology and Treatment of Hypertrophic Cardiomyopathy: New Perspectives

  2021cites this paper
• Cardiopulmonary Exercise Test in Patients with Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis

  2021cites this paper
• JCS/JHRS 2019 guideline on non‐pharmacotherapy of cardiac arrhythmias

  2021cites this paper
• Inhibition of mTOR or MAPK ameliorates vmhcl/myh7 cardiomyopathy in zebrafish

  2021cites this paper
• Myocardial early systolic lengthening predicts mid-term outcomes in patients with hypertrophic cardiomyopathy

  2021cites this paper
• Cardiovascular Magnetic Resonance Imaging and Heart Failure

  2021cites this paper
• Validation of the new American College of Cardiology/American Heart Association Guidelines for the risk stratification of sudden cardiac death in a large Mediterranean cohort with Hypertrophic Cardiomyopathy.

  2021cites this paper
• Left atrial dysfunction as marker of poor outcome in patients with hypertrophic cardiomyopathy.

  2020cites this paper
• Epidemiology of Pediatric Hypertrophic Cardiomyopathy in a 10-Year Medicaid Cohort

  2020cites this paper
• The feasibility and diagnostic value of intravoxel incoherent motion diffusion-weighted imaging in the assessment of myocardial fibrosis in hypertrophic cardiomyopathy patients.

  2020cites this paper
• LGE for Risk Stratification in Primary Prevention in Children With HCM.

  2020cites this paper
• Parámetros ecocardiográficos y electrocardiográficos en caninos atletas de la raza Border Collie en gran altitud

  2020cites this paper
• Evaluation of the effectiveness of pharmacotherapy for brain and heart diseases by monitoring the effects of drugs

  2020cites this paper
• Characterization and validation of a preventative therapy for hypertrophic cardiomyopathy in a murine model of the disease

  2020cites this paper
• Post-Mortem Cardiac Magnetic Resonance for the Diagnosis of Hypertrophic Cardiomyopathy

  2020cites this paper
• Antitachycardia Pacing for Shock Prevention in Patients with Hypertrophic Cardiomyopathy and Ventricular Tachycardia.

  2020cites this paper
• Cardiac troponin I is associated with non-sustained ventricular tachycardia in patients with hypertrophic obstructive cardiomyopathy

  2020cites this paper
• Cardiomyopathies: Dilated, Restrictive/Infiltrative, and Hypertrophic Cardiomyopathies

  2020cites this paper
• Clinical outcomes in adult athletes with hypertrophic cardiomyopathy: a 7-year follow-up study

  2020cites this paper
• Late gadolinium enhancement location assessed by magnetic resonance and arrhythmogenic risk in hypertrophic cardiomyopathy.

  2020influential citation
• 2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias: Executive summary

  2020cites this paper
• Cardiovascular magnetic resonance T2* mapping for the assessment of cardiovascular events in hypertrophic cardiomyopathy

  2020cites this paper
• Obstructive sleep apnea is associated with nonsustained ventricular tachycardia in patients with hypertrophic obstructive cardiomyopathy.

  2019cites this paper
• Hypertrophic cardiomyopathy: genetics and clinical perspectives.

  2019cites this paper
• CARDIOPROTECTIVE EFFECT OF METABOLIC PREPARATION IN EXPERIMENTAL DOXORUBICIN CARDIOMYOPATHY.

  2019cites this paper
• Impaired calcium handling and mitochondrial metabolic dysfunction as early markers of hypertrophic cardiomyopathy.

  2019cites this paper
• Predictive Values of Apelin for Myocardial Fibrosis in Hypertrophic Cardiomyopathy.

  2019cites this paper
• The role of echocardiography in management of hypertrophic cardiomyopathy

  2019cites this paper
• Hypertrophic Cardiomyopathy

  2019cites this paper
• 2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias.

  2019cites this paper
• Advances in cardiovascular imaging

  2019cites this paper
• Update : Arrhythmias ( XI ) Sudden Death

  2019influential citation
• Prognostic impact of mitral L-wave in patients with hypertrophic cardiomyopathy without risk factors for sudden cardiac death

  2019cites this paper
• 2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias

  2019cites this paper
• 2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias

  2019cites this paper
• Burden and trends of arrhythmias in hypertrophic cardiomyopathy and its impact of mortality and resource utilization

  2019cites this paper
• Left ventricular twist in hypertrophic cardiomyopathy

  2019cites this paper
• T cardiac magnetic resonance intravoxel incoherent motion in evaluating microvascular dysfunction of hypertrophic cardiomyopathy patients

  2019influential citation
• [The role of cardiovascular magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Part I].

  2018cites this paper
• Comparison of the Prognostic Usefulness of the European Society of Cardiology and American Heart Association/American College of Cardiology Foundation Risk Stratification Systems for Patients With Hypertrophic Cardiomyopathy

  2018cites this paper
• Sudden Cardiac Death Risk Assessment

  2018cites this paper
• Heart muscle disease management in aircrew

  2018cites this paper
• Fibrosis and wall thickness affect ventricular repolarization dynamics in hypertrophic cardiomyopathy

  2018cites this paper
• Modeling Cardiac Hemodynamic Response During Exercise in Health and Hypertrophic Cardiomyopathy

  2018cites this paper
• A comparative study on the cardiac morphology and vertical jump height of adolescent black South African male and female amateur competitive footballers

  2018cites this paper
• Prognosis of adult obstructive hypertrophic cardiomyopathy patients with different morphological types after surgical myectomy†

  2018cites this paper
• Approach to the Initial and Follow-Up Visits

  2018cites this paper
• Prevention of Sudden Cardiac Death in Hypertrophic Cardiomyopathy: What has Changed in The Guidelines?

  2018cites this paper
• 86 – Ventricular Arrhythmias in Hypertrophic Cardiomyopathy: Sudden Death, Risk Stratification, and Prevention With Implantable Defibrillators

  2018cites this paper
• Medical Therapy: From Beta-Blockers to Disopyramide

  2018cites this paper
• Modeling of hypertrophic cardiomyopathy and assessment of gene therapy in human iPSC-derived cardiomyocytes

  2018cites this paper
• Sexuální aktivita a kardiovaskulární onemocnění, erektilní dysfunkce jako prediktor ischemické choroby srdeční

  2018cites this paper
• Cardiovascular magnetic resonance imaging in heart failure

  2018cites this paper
• Gene therapy strategies in the treatment of hypertrophic cardiomyopathy

  2018cites this paper
• Mechanical dispersion and global longitudinal strain by speckle tracking echocardiography: Predictors of appropriate implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy

  2017cites this paper
• Eligibility and Disquali fi cation Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Preamble, Principles, and General Considerations

  2017cites this paper
• Myofilament protein dynamics modulate EAD formation in human hypertrophic cardiomyopathy.

  2017cites this paper
• Sexual activity and cardiovascular disease, erectile dysfunction as a predictor of ischemic heart disease

  2017cites this paper
• Incremental benefit of late gadolinium cardiac magnetic resonance imaging for risk stratification in patients with hypertrophic cardiomyopathy

  2017cites this paper
• The systolic paradox in hypertrophic cardiomyopathy

  2017cites this paper
• The hemodynamic impact of acute nasal continuous positive airway pressure treatment in hypertrophic cardiomyopathy: is it safe?

  2017cites this paper
• Impact of Demographic Features, Lifestyle, and Comorbidities on the Clinical Expression of Hypertrophic Cardiomyopathy

  2017cites this paper
• Association between ventricular filling patterns and the extent of late enhancement on magnetic resonance imaging in patients with hypertrophic cardiomyopathy.

  2017cites this paper
• Cardiomiopatía hipertrófica: experiencia de 5 años

  2017cites this paper
• Successful MACE risk stratification in hypertrophic cardiomyopathy patients using different 2D speckle-tracking TTE approaches.

  2017cites this paper
• Primary ventricular tachycardia in paediatric population in a tertiary centre

  2017cites this paper
• Association between ventricular filling patterns and the extent of late enhancement on magnetic resonance imaging in patients with hypertrophic cardiomyopathy.

  2017cites this paper
• ESC sudden‐death risk model in hypertrophic cardiomyopathy: Incremental value of quantitative contrast‐enhanced CMR in intermediate‐risk patients

  2017cites this paper
• Disease Severity and Exercise Testing Reduce Subcutaneous Implantable Cardioverter-Defibrillator Left Sternal ECG Screening Success in Hypertrophic Cardiomyopathy

  2017cites this paper
• Helical distribution of hypertrophy in patients with hypertrophic cardiomyopathy: prevalence and clinical implications

  2017cites this paper
• Pulmonary hypertension and clinical correlates in hypertrophic cardiomyopathy.

  2017cites this paper
• 16 – Defibrillation Therapy

  2017cites this paper
• ANALYSIS OF THE LONGXTERM RESULTS OF COMBINED MYECTOMY IN PATIENTS WITH HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY

  2016cites this paper
• Role of quantitative myocardial positron emission tomography for risk stratification in patients with hypertrophic cardiomyopathy: a 2016 reappraisal

  2016cites this paper
• How Hypertrophic Cardiomyopathy Became a Contemporary Treatable Genetic Disease With Low Mortality: Shaped by 50 Years of Clinical Research and Practice.

  2016cites this paper
• Strain echocardiography is related to fibrosis and ventricular arrhythmias in hypertrophic cardiomyopathy

  2016cites this paper
• Hypertrophic Cardiomyopathy in Children, Adolescents, and Young Adults Associated With Low Cardiovascular Mortality With Contemporary Management Strategies

  2016cites this paper
• LGE Means Better Selection of HCM Patients for Primary Prevention Implantable Defibrillators.

  2016cites this paper